From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML

Last Updated: Tuesday, May 13, 2025

Researchers investigated the combined targeting of CD70 and CD33 to overcome acute myeloid leukemia antigen heterogeneity. They found that CD70-targeted CAR T cells secreting a CD33 T-cell–engaging antibody molecule showed feasibility in overcoming AML heterogeneity and leveraging patients’ bystander T cells.

Blood
Advertisement
News & Literature Highlights
Advertisement
Advertisement